Evidence map›Paper›PMID 41775686›Full record

ArticleNature communications2026

Integrative epigenomic landscape of Alzheimer's Disease brains reveals oligodendrocyte molecular perturbations associated with tau.

Stephanie R Oatman, Joseph S Reddy, Amin Atashgaran, Xue Wang, Yuhao Min, Zachary Quicksall, Floor Vanelderen, Minerva M Carrasquillo, Chia-Chen Liu, Yu Yamazaki and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Stephanie R OatmanDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Joseph S ReddyDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-1783-4453
Amin AtashgaranDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0009-0002-9051-0989
Xue WangDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-1964-4124
Yuhao MinDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-8775-8743
Zachary QuicksallDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-8791-0925
Floor VanelderenDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-7647-6318
Minerva M CarrasquilloDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-3231-9134
Chia-Chen LiuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Yu YamazakiDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-0806-4960
Thuy T NguyenDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-8879-7090
Michael HeckmanDepartment of Quantitative Health Sciences, Mayo Clinic, Jacksonville, FL, USA.
Na ZhaoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-8648-9422
Michael DeTureDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Melissa E MurrayDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-7379-2545
Guojun BuDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-3491-1016
Takahisa KanekiyoDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-6751-9374
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-7189-7917
Mariet AllenDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0002-2685-427X
Nilüfer Ertekin-TanerDepartment of Neuroscience, Mayo Clinic, Jacksonville, FL, USA. taner.nilufer@mayo.edu.ORCID 0000-0003-4436-8889

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
Peripheral and Central Biomarkers of Alzheimer's Disease in Diverse CohortsU19AG074879 · NIA · MAYO CLINIC JACKSONVILLE · PI Minerva Maria Carrasquillo · 2023 to 2026
$42.0M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Integrating the exposome and methylome to inform brain molecular changes in ADRD across established diverse cohorts.U01AG046139 · NIA · UNIVERSITY OF FLORIDA · PI ERTEKIN-TANER, NILUFER, FUNK, CORY · 2013 to 2022
$24.6M
Integrative translational discovery of vascular risk factors in aging and dementiaRF1AG051504 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN, ERTEKIN-TANER, NILUFER · 2015 to 2019
$9.8M
Harnessing Molecular Networks of Resilience for Therapeutic Discoveries in ADR01AG061796 · NIA · MAYO CLINIC JACKSONVILLE · PI ERTEKIN-TANER, NILUFER · 2018 to 2022
$5.7M
ApoE pathway in cerebrovascular Aβ clearance in Alzheimer’s diseaseR37AG027924 · NIA · MAYO CLINIC JACKSONVILLE · PI BU, GUOJUN · 2017 to 2020
$2.4M
NIA NIH HHS R01 AG061796NIA NIH HHS RF1 AG051504NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG046139NIA NIH HHS U19 AG074879U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) P50AG016574U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging) R37AG027924
6 · The paper itself

Abstract

Alzheimer's disease (AD) brains have variable neuropathologic and biochemical changes. Capturing epigenetic factors associated with this variability can reveal novel biological insights into AD pathophysiology. Here, we conduct an epigenome-wide association study of DNA methylation in 472 AD brains with neuropathologic and biochemical brain protein levels core to AD pathogenesis. Using a novel regional methylation (rCpGm) approach, we identify 5478 significant associations, 99.7% of which associate with tau biochemical measures, and 93 concordant associations in external datasets. Transcriptome-methylome integration reveals enrichment in oligodendrocyte genes, including known AD risk gene BIN1, myelination genes MYRF, MBP and MAG previously implicated in AD, and novel genes like LDB3. Further characterization of these perturbations in independent AD and primary tauopathy datasets highlights consistent tau-related associations. In summary, we uncover the integrative epigenomic landscape of AD, demonstrate tau-related oligodendrocyte gene perturbations as a common potential pathomechanism across tauopathies and share findings via our Multiomic Atlas.

Indexed as

Alzheimer DiseaseBrainOligodendrogliatau ProteinsAdaptor Proteins, Signal TransducingAgedAged, 80 and overDNA MethylationEpigenesis, GeneticEpigenomeEpigenomicsFemaleGenome-Wide Association StudyHumansMaleNuclear ProteinsAdaptor Proteins, Signal TransducingBIN1 protein, humanNuclear Proteinstau ProteinsTumor Suppressor Proteins

Identifiers

PMID41775686
PMCPMC12957399

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.